Lisata Therapeutics Crecimiento futuro

Future controles de criterios 0/6

Se prevé que los beneficios de Lisata Therapeutics disminuyan a un ritmo anual de 8.5%, mientras que sus ingresos anuales crecerán a un ritmo de 90.5% por año. Se espera que el BPA crezca en un 11.6% al año.

Información clave

-6.7%

Tasa de crecimiento de los beneficios

14.8%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Biotechs	34.8%
Tasa de crecimiento de los ingresos	95.3%
Rentabilidad financiera futura	n/a
Cobertura de analistas	Low
Última actualización	13 Aug 2024

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Previsiones de crecimiento de beneficios e ingresos

LSE:0HS8 - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2026	N/A	-26	N/A	N/A	2
12/31/2025	N/A	-29	N/A	N/A	2
12/31/2024	N/A	-25	N/A	N/A	2
6/30/2024	N/A	-21	-20	-20	N/A
3/31/2024	N/A	-20	-19	-19	N/A
12/31/2023	N/A	-21	-20	-20	N/A
9/30/2023	N/A	-21	-22	-22	N/A
6/30/2023	N/A	-54	-23	-23	N/A
3/31/2023	N/A	-56	-24	-24	N/A
12/31/2022	N/A	-54	-21	-21	N/A
9/30/2022	N/A	-55	-20	-19	N/A
6/30/2022	N/A	-25	-21	-20	N/A
3/31/2022	N/A	-24	-20	-20	N/A
12/31/2021	N/A	-27	-22	-22	N/A
9/30/2021	N/A	-26	-23	-23	N/A
6/30/2021	N/A	-25	-22	-22	N/A
3/31/2021	N/A	-12	-13	-13	N/A
12/31/2020	N/A	-8	-9	-9	N/A
9/30/2020	N/A	-8	-7	-7	N/A
6/30/2020	N/A	-7	-8	-8	N/A
3/31/2020	N/A	-19	-18	-18	N/A
12/31/2019	N/A	-19	-19	-19	N/A
9/30/2019	N/A	-18	-18	-18	N/A
6/30/2019	N/A	-17	-18	-18	N/A
3/31/2019	N/A	-16	-19	-19	N/A
12/31/2018	N/A	-16	-20	-20	N/A
9/30/2018	N/A	-17	-21	-21	N/A
6/30/2018	N/A	-17	-23	-22	N/A
3/31/2018	N/A	-14	N/A	-17	N/A
12/31/2017	N/A	-16	N/A	-21	N/A
9/30/2017	N/A	-18	N/A	-20	N/A
6/30/2017	N/A	-20	N/A	-20	N/A
3/31/2017	-7	-26	N/A	-26	N/A
12/31/2016	N/A	-31	N/A	-24	N/A
9/30/2016	8	-59	N/A	-29	N/A
6/30/2016	13	-64	N/A	-32	N/A
3/31/2016	27	-74	N/A	-33	N/A
12/31/2015	22	-81	N/A	-39	N/A
9/30/2015	20	-59	N/A	-41	N/A
6/30/2015	18	-65	N/A	-46	N/A
3/31/2015	17	-60	N/A	-50	N/A
12/31/2014	18	-55	N/A	-47	N/A
9/30/2014	17	-56	N/A	-43	N/A
6/30/2014	16	-48	N/A	-36	N/A
3/31/2014	16	-44	N/A	-31	N/A
12/31/2013	15	-39	N/A	-27	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Se prevé que 0HS8 siga sin ser rentable en los próximos 3 años.

Beneficios vs. Mercado: Se prevé que 0HS8 siga sin ser rentable en los próximos 3 años.

Beneficios de alto crecimiento: Se prevé que 0HS8 siga sin ser rentable en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que 0HS8 no tenga ingresos el año que viene.

Ingresos de alto crecimiento: Se prevé que 0HS8 no tenga ingresos el año que viene.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de 0HS8 se prevé que sea elevada dentro de 3 años.

Lisata Therapeutics Crecimiento futuro

Future controles de criterios 0/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Forecast to breakeven in 2025

Recent updates

Lisata Therapeutics, Inc. Announces First Patient Treated in the Second-Line Cholangiocarcinoma Cohort of the BOLSTER Trial

Lisata Therapeutics, Inc. to Report Q2, 2024 Results on Aug 12, 2024

Lisata Therapeutics, Inc. Announces Completion of Enrollment in its Phase 2a BOLSTER Trial of Certepetide in First-Line Cholangiocarcinoma

Lisata Therapeutics, Inc. Certepetide Shows Promise in Improving Standard Treatment for Intrahepatic Cholangiocarcinoma in A Preclinical Model

Lisata Therapeutics, Inc. to Report Q1, 2024 Results on May 09, 2024

Lisata Therapeutics, Inc., Annual General Meeting, Jun 27, 2024

Lisata Therapeutics, Inc and Qilu Pharmaceutical Co., Ltd Announce First Patient Treated in Qilu’s Phase 2 Trial in China of LSTA1 in Patients with Metastatic Pancreatic Ductal Adenocarcinoma

Lisata Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to LSTA1 for the Treatment of Osteosarcoma

Lisata Therapeutics, Inc. to Report Fiscal Year 2023 Results on Feb 29, 2024

Lisata Therapeutics, Inc. Announces First Patient Treated in the Phase 2A Trial of Lsta1 in Patients with Glioblastoma Multiforme

Lisata Therapeutics, Inc. Announces Completion of Enrollment in Phase 2B Ascend Trial of Lsta1 in Metastatic Pancreatic Ductal Adenocarcinoma

Lisata Therapeutics, Inc. Announces LSTA1 as A Treatment for Solid Tumor Cancers in Combination with Other Anti-Cancer Agents

New major risk - Revenue and earnings growth

Lisata Therapeutics, Inc. to Report Q3, 2023 Results on Nov 02, 2023

Lisata Therapeutics, Inc. Announces First Patient Treated in the Cholangiocarcinoma Cohort of the BOLSTER Trial of LSTA1

Lisata Therapeutics, Inc. Announces Outcome of Interim Futility Analysis for Its Phase 2B Ascend Trial of Lsta1 in Metastatic Pancreatic Ductal Adenocarcinoma

Lisata Therapeutics, Inc. to Report Q2, 2023 Results on Aug 14, 2023

Lisata Therapeutics, Inc. Announces Retirement of Erkki Ruoslahti from Board of Directors

Lisata Therapeutics Announces Enhancements to Ongoing Phase 2B Ascend Trial of LSTA1

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Caladrius Biosciences, Inc. (NasdaqCM:CLBS) completed the acquisition of Cend Therapeutics Inc.

Caladrius Biosciences, Inc. (NasdaqCM:CLBS) completed the acquisition of Cend Therapeutics Inc.

Insufficient new directors

Nasdaq Grants Caladrius Biosciences an Extension Through February 13, 2023 to Evidence Compliance with the Bid Price Requirement

Caladrius Biosciences, Inc Completes Enrollment in Phase 1b Study of CLBS201 for the Treatment of Diabetic Kidney Disease

Caladrius Biosciences, Inc. to Report Q2, 2022 Results on Aug 04, 2022

Insufficient new directors

Caladrius Biosciences and Cend Therapeutics Announce Publication of Pancreatic Cancer Trial Data in the Lancet Gastroenterology and Hepatology

Insufficient new directors

Caladrius Biosciences Provides Update on Phase 2b FREEDOM Trial of XOWNA(R) in Coronary Microvascular Dysfunction

Caladrius Biosciences Inc. Announces IDMC Recommendation to Advance Clbs201 Trial for the Treatment of Diabetic Kidney Disease

Caladrius Biosciences, Inc. (NasdaqCM:CLBS) entered into a definitive merger agreement to acquire Cend Therapeutics Inc. for $38.1 million.

Insufficient new directors

Caladrius Biosciences, Inc. Treats First Patient in the Phase 1B Trial of CLBS201 for the Treatment of Diabetic Kidney Disease

Todd C. Girolamo Intent to Resign as Chief Legal Officer, Senior Vice President of Corporate Development and Corporate Secretary of Caladrius Biosciences, Inc., Effective March 14, 2022

Forecast to breakeven in 2025

Caladrius Biosciences to Assess Its CLBS201 CD34+ Cell Therapy in Diabetic Kidney Disease

Caladrius Biosciences, Inc. Announces Orphan Drug Designation for CLBS12 for the Treatment of Buerger’s Disease

Caladrius Biosciences, Inc. to Report Q4, 2020 Results on Feb 25, 2021

Caladrius Biosciences, Inc. announced that it has received $25 million in funding

Caladrius Biosciences, Inc. announced that it expects to receive $25 million in funding

Previsiones de crecimiento de beneficios e ingresos

Previsiones de crecimiento futuro de los analistas

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

Descubre empresas en crecimiento